RenovoRx (RNXT) has now tripled since August. Q3 is already tracking above Q2.

RenovoRx Inc. (NASDAQ: RNXT) was at $0.87 in mid-July. It closed at $2.52 on September 4. That's a 190% move in seven weeks from a company that generates less than $1 million per quarter in revenue. The first leg of the move was covered in our earlier analysis when the stock went from $0.87 to $1.40 on the Q2 beat and Phase III enrollment completion. The question now is what's driving the second leg, from $1.40 to $2.52, and whether the fundamental picture justifies where the stock is sitting today.

What changed since the first move

Three things have accumulated since the August Q2 report. First, Q3 is tracking above Q2 by management's own account. CEO Shaun Bagai stated explicitly on the August earnings call that Q3 revenue was already trending to exceed the Q2 record of $909K based on repeat ordering patterns and the commercial pipeline. That statement is now roughly four to five weeks old. If it's holding, Q3 would be the fourth consecutive record quarter in a row — Q4 2025 to Q3 2026 without a down quarter. For a company that had $238K in revenue in Q4 2025, that trajectory is unusual enough to draw attention.

Second, analyst coverage has firmed up. Four analysts now cover RNXT with a consensus moderate buy, an average price target of $8.50, and a high target of $14.00. A buy rating affirmation cited Phase III TIGeR-PaC trial progress as a near-term catalyst and specifically mentioned RenovoRx's "promising product launch and strategic expansion" as justification. None of that is price-moving on its own, but it gives institutional cover for investors building positions at higher prices than the mid-August levels.

Third, the PanTheR registry trial has been generating updates. PanTheR is a real-world evidence study tracking outcomes from commercial RenovaCath use at cancer centers. Unlike the Phase III TIGeR-PaC trial, which has a fixed endpoint in H2 2027, PanTheR produces rolling data as more centers use the product. Positive interim observations from PanTheR have been cited in recent coverage as supporting the commercial adoption narrative. Registry data isn't as definitive as Phase III results, but it provides supporting evidence while the randomized trial runs.

The commercial funnel — where the centers actually stand

At the Q2 report, RenovoRx had 21 active commercial cancer centers, up from 16 in Q1, with a total commercial funnel of 63 prospective locations. The target was 36 active centers by year-end 2026. If the company reaches that target, it would roughly double the active center count from Q2 levels. Each new active center adds an annualized base of recurring revenue as physicians establish ordering patterns. The revenue growth from Q1 ($563K) to Q2 ($909K) was partly volume per existing center and partly new center additions. Both levers are still in play for Q3.

The 200 total target centers management has identified represents the eventual addressable commercial market for the RenovaCath device in pancreatic and adjacent cancer indications. At 21 active centers and 200 total potential, the company is about 10% penetrated in its own defined market. That's the commercial upside the stock is starting to price in, well ahead of the clinical trial data that would validate the platform for the remaining 90%.

What the stock is pricing in now

At $2.52 with roughly 45 million shares outstanding, RNXT has a market cap of approximately $113 million. Full-year 2026 guidance is $3.75 to $4.25 million in revenue. That's a price-to-sales ratio above 25x on current-year revenue. For a company with 84% gross margins and a Phase III trial reading out in H2 2027, that multiple is not insane if the trial is positive — it's actually modest relative to what successful oncology device companies trade at post-approval. If TIGeR-PaC data shows improved outcomes versus standard of care for locally advanced pancreatic cancer, the addressable market and the revenue trajectory change dramatically. The analyst $8.50 average target is essentially pricing in a world where that happens.

If the trial is negative or inconclusive, the commercial device business alone — $4 million in revenue at 84% margins but still losing money on operating expenses of roughly $12 million annually — cannot support a $113 million market cap. The math only works with the trial. That's the same binary it was at $1.40. The stock has moved 80% higher, but the binary itself hasn't resolved. It's still 15 months away.

The one thing beginners should take away

A 190% move from a micro-cap medical device company in seven weeks attracts attention for a reason. The fundamentals supporting the move are real: four consecutive record quarters, Q3 tracking above Q2, Phase III enrollment complete, analyst upgrades, a $9.5 million cash position, and a commercial pipeline that's 10% penetrated in its own defined market. None of that is manufactured. But the stock has now moved from pricing in uncertainty about all of those things to pricing in a favorable resolution of the one thing that can't be known yet — the TIGeR-PaC Phase III outcome in H2 2027. Buying RNXT at $2.52 versus $1.40 means paying a higher price for the same binary event, with the same odds of it resolving favorably. The commercial story gives you reasons to be interested. The trial is still what you're actually betting on.